

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: HNLACETRT

(Page 1 of 2)

DOCTOR'S ORDERS							
Height cm	Weight	kg	BSA =		x Weight (kg) =	m^2	
<u> </u>					600		
REMINDER: Please ens			us bleomyc			Alert Form	
DATE:	То	be given:		Day	/(s):		
Date of Previous Cycle:							
☐ Delay treatment	week(s)						
day of treatment: CBC & diff, platelets, magnesium, calcium, albumin, electrolytes, creatinine							
May proceed with doses as written if less than Grade 2: rash, diarrhea, stomatitis							
Dose modification for: Severe acneiform rash diarrhea stomatitis							
Rate modification for: Allergic/Hypersensitivity reactions							
Proceed with treatment based on bloodwork from							
PREMEDICATIONS: F							
diphenhydrAMINE 50 mg ☐ Other:	g PO 30 to 60 m	ninutes prior to e	each Cetuxir	nab dose			
	** Have Hyner	sansitivity Read	rtion Tray a	nd protocol avail	lahlo**		
TREATMENT:	nave riyper.	schollivity Rout	otion may a	na protocor avan	idolo		
	ıre. Pulse. Resp	iration. Blood P	ressure pre -	Cetuximab infusio	on. halfway through in	fusion and	
VITAL SIGNS: Temperature, Pulse, Respiration, Blood Pressure pre -Cetuximab infusion, halfway through infusion and one hour post infusion.* Patients are to be observed visually for the first 15 minutes of Cetuximab infusion.							
Flush cetuximab line post infusion with Normal Saline (0.9% Sodium Chloride Injection)							
DAY minus 7 from radiation start date:							
		2.4.504			,		
				mg IV over 2 hour	rs (use 0.2 micron in-l	ine filter)	
Infusion rate not to	o exceed to me	y/minute.					
Observe for 1 hour following end of 1 st and 2 nd infusions (day minus 7 and day 1)							
May discontinue observation period and vital signs if no infusion reaction for 2 consecutive doses.							
Concurrent on days with Radiation Therapy weekly X 2 weeks OR 3 weeks (select one)							
	d) 050/	2 V DO A			(
cetuximab (subsequent dose) 250 mg/m² X BSA = mg IV over 1 hour (use 0.2 micron in-line filter) (Observation period during RT)							
(Observation period during	91(1)						
☐ Dose Modifica	ation:	mg/m² x BS	A =	mg			
□ D	-:)/ f	II : - /I- :		_		
Decrease infusion rate by 50% for previous allergic/hypersensitivity reaction.							
Start time of observation: End time of observation:							
Life time of observation	-						
POST-CHEMO Magnesium Supplementation: (see protocol for magnesium supplementation guidelines)							
magnesium sulfate 2 G IV in 50 mL NS over 30 minutes							
magnesium sulfate 5 G IV in 100 mL NS over 3 hours							
RN to assess for severe acneiform rash and diarrhea prior to EACH cetuximab infusion							
Notify Doctor of any signs and symptoms of toxicity prior to administering cetuximab							
DOCTOR'S SIGNATUI	KE:				SIGNATURE:		
					UC:		



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: HNLACETRT

(Page 2 of 2)

DATE:	To be given:	Day(s):				
RETURN APPOINTMENT ORDERS						
Book weekly chemo for duration of R	T X weeks					
Return in weeks for Doctor						
Last Cycle. Return in w	eek(s).					
CBC & diff, platelets, magnesium, calcium, albumin, sodium, potassium, creatinine, prior to next physician appointment						
☐ re-check magnesium level in 1 we	ek					
OR ☐ patient will be seen in Patient						
Day 22: CBC & diff, platelets, magnereatinine						
Day 36: CBC & diff, platelets, magr	nesium, calcium, album	in, sodium, potassium,				
☐ Tests:						
☐ Consults:						
☐ See general orders sheet for ac	Iditional requests.					
DOCTOR'S SIGNATURE:			SIGNATURE: UC:			